Cargando…
Current trends in drug metabolism and pharmacokinetics
Pharmacokinetics (PK) is the study of the absorption, distribution, metabolism, and excretion (ADME) processes of a drug. Understanding PK properties is essential for drug development and precision medication. In this review we provided an overview of recent research on PK with focus on the followin...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900561/ https://www.ncbi.nlm.nih.gov/pubmed/31867160 http://dx.doi.org/10.1016/j.apsb.2019.10.001 |
_version_ | 1783477372996026368 |
---|---|
author | Li, Yuhua Meng, Qiang Yang, Mengbi Liu, Dongyang Hou, Xiangyu Tang, Lan Wang, Xin Lyu, Yuanfeng Chen, Xiaoyan Liu, Kexin Yu, Ai-Ming Zuo, Zhong Bi, Huichang |
author_facet | Li, Yuhua Meng, Qiang Yang, Mengbi Liu, Dongyang Hou, Xiangyu Tang, Lan Wang, Xin Lyu, Yuanfeng Chen, Xiaoyan Liu, Kexin Yu, Ai-Ming Zuo, Zhong Bi, Huichang |
author_sort | Li, Yuhua |
collection | PubMed |
description | Pharmacokinetics (PK) is the study of the absorption, distribution, metabolism, and excretion (ADME) processes of a drug. Understanding PK properties is essential for drug development and precision medication. In this review we provided an overview of recent research on PK with focus on the following aspects: (1) an update on drug-metabolizing enzymes and transporters in the determination of PK, as well as advances in xenobiotic receptors and noncoding RNAs (ncRNAs) in the modulation of PK, providing new understanding of the transcriptional and posttranscriptional regulatory mechanisms that result in inter-individual variations in pharmacotherapy; (2) current status and trends in assessing drug–drug interactions, especially interactions between drugs and herbs, between drugs and therapeutic biologics, and microbiota-mediated interactions; (3) advances in understanding the effects of diseases on PK, particularly changes in metabolizing enzymes and transporters with disease progression; (4) trends in mathematical modeling including physiologically-based PK modeling and novel animal models such as CRISPR/Cas9-based animal models for DMPK studies; (5) emerging non-classical xenobiotic metabolic pathways and the involvement of novel metabolic enzymes, especially non-P450s. Existing challenges and perspectives on future directions are discussed, and may stimulate the development of new research models, technologies, and strategies towards the development of better drugs and improved clinical practice. |
format | Online Article Text |
id | pubmed-6900561 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-69005612019-12-20 Current trends in drug metabolism and pharmacokinetics Li, Yuhua Meng, Qiang Yang, Mengbi Liu, Dongyang Hou, Xiangyu Tang, Lan Wang, Xin Lyu, Yuanfeng Chen, Xiaoyan Liu, Kexin Yu, Ai-Ming Zuo, Zhong Bi, Huichang Acta Pharm Sin B Review Pharmacokinetics (PK) is the study of the absorption, distribution, metabolism, and excretion (ADME) processes of a drug. Understanding PK properties is essential for drug development and precision medication. In this review we provided an overview of recent research on PK with focus on the following aspects: (1) an update on drug-metabolizing enzymes and transporters in the determination of PK, as well as advances in xenobiotic receptors and noncoding RNAs (ncRNAs) in the modulation of PK, providing new understanding of the transcriptional and posttranscriptional regulatory mechanisms that result in inter-individual variations in pharmacotherapy; (2) current status and trends in assessing drug–drug interactions, especially interactions between drugs and herbs, between drugs and therapeutic biologics, and microbiota-mediated interactions; (3) advances in understanding the effects of diseases on PK, particularly changes in metabolizing enzymes and transporters with disease progression; (4) trends in mathematical modeling including physiologically-based PK modeling and novel animal models such as CRISPR/Cas9-based animal models for DMPK studies; (5) emerging non-classical xenobiotic metabolic pathways and the involvement of novel metabolic enzymes, especially non-P450s. Existing challenges and perspectives on future directions are discussed, and may stimulate the development of new research models, technologies, and strategies towards the development of better drugs and improved clinical practice. Elsevier 2019-11 2019-10-18 /pmc/articles/PMC6900561/ /pubmed/31867160 http://dx.doi.org/10.1016/j.apsb.2019.10.001 Text en © 2019 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Review Li, Yuhua Meng, Qiang Yang, Mengbi Liu, Dongyang Hou, Xiangyu Tang, Lan Wang, Xin Lyu, Yuanfeng Chen, Xiaoyan Liu, Kexin Yu, Ai-Ming Zuo, Zhong Bi, Huichang Current trends in drug metabolism and pharmacokinetics |
title | Current trends in drug metabolism and pharmacokinetics |
title_full | Current trends in drug metabolism and pharmacokinetics |
title_fullStr | Current trends in drug metabolism and pharmacokinetics |
title_full_unstemmed | Current trends in drug metabolism and pharmacokinetics |
title_short | Current trends in drug metabolism and pharmacokinetics |
title_sort | current trends in drug metabolism and pharmacokinetics |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900561/ https://www.ncbi.nlm.nih.gov/pubmed/31867160 http://dx.doi.org/10.1016/j.apsb.2019.10.001 |
work_keys_str_mv | AT liyuhua currenttrendsindrugmetabolismandpharmacokinetics AT mengqiang currenttrendsindrugmetabolismandpharmacokinetics AT yangmengbi currenttrendsindrugmetabolismandpharmacokinetics AT liudongyang currenttrendsindrugmetabolismandpharmacokinetics AT houxiangyu currenttrendsindrugmetabolismandpharmacokinetics AT tanglan currenttrendsindrugmetabolismandpharmacokinetics AT wangxin currenttrendsindrugmetabolismandpharmacokinetics AT lyuyuanfeng currenttrendsindrugmetabolismandpharmacokinetics AT chenxiaoyan currenttrendsindrugmetabolismandpharmacokinetics AT liukexin currenttrendsindrugmetabolismandpharmacokinetics AT yuaiming currenttrendsindrugmetabolismandpharmacokinetics AT zuozhong currenttrendsindrugmetabolismandpharmacokinetics AT bihuichang currenttrendsindrugmetabolismandpharmacokinetics |